- Investing.com
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis. It also provides pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a stem cell gene therapy. The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.
Metrics to compare | 4599 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4599PeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.4x | −4.0x | −0.6x | |
PEG Ratio | −0.75 | −0.08 | 0.00 | |
Price/Book | 2.3x | 4.1x | 2.6x | |
Price / LTM Sales | - | 24.2x | 3.2x | |
Upside (Analyst Target) | 174.5% | 28.2% | 42.3% | |
Fair Value Upside | Unlock | 9.5% | 5.7% | Unlock |